phenylmethyl 2-(3-nitrophenyl)acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylmethyl 2-(3-nitrophenyl)acetate
• 英文别名: benzyl 3-nitrophenylacetate；Phenylmethyl 2-(3-nitrophenvl)acetate；benzyl 2-(3-nitrophenyl)acetate
• 化学式: C₁₅H₁₃NO₄
• 分子量: 271.273
• InChiKey: RJQMPUQTLOZERR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-硝基苯乙酸 在 苯甲醇 作用下， 以 N-甲基乙酰胺 、 草酰氯 、 水 、 1,2-二氯乙烷 为溶剂， 生成 phenylmethyl 2-(3-nitrophenyl)acetate
  参考文献：
  名称：

  Thiazolidine derivatives, preparation thereof and drugs containing samem

  摘要：

  公式（I）的衍生物，它们的盐，所述衍生物的制备以及含有相同物质的药物。公式（I）的化合物具有有趣的药理学特性。所述化合物对胆囊收缩素（CCK）和胃泌素受体具有高亲和力，因此在治疗和预防影响神经系统和消化道的CCK和胃泌素相关疾病中很有用。

  公开号：

  US05633270A1

文献信息

• Thiazolidine derivatives, their preparation and the medicaments
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05686622A1

  公开（公告）日：1997-11-11

  Thiazolidine derivatives of formula (I), in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in the specification. The invention also concerns the salts of these derivatives, the preparation thereof and drugs containing same. ##STR1##

  化学式（I）中的噻唑啉衍生物，其中R.sub.1，R.sub.2，R.sub.3，R.sub.4和R.sub.5如规范中所定义。本发明还涉及这些衍生物的盐，其制备方法以及含有它们的药物。## STR1 ##
• Integrin inhibitors and their methods of use
  申请人：——

  公开号：US20020019402A1

  公开（公告）日：2002-02-14

  The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a &agr; v &bgr; 3 , &agr; v &bgr; 6 , &agr; 5 &bgr; 1 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  该发明涉及新型化合物，对预防和治疗疾病（如整合素受体介导的疾病，特别是由整合素受体介导的疾病或病况，如αvβ3、αvβ6、α5β1等）具有有效性。该发明涵盖了新型化合物、其药用可接受盐、药物组合物以及预防和治疗此类疾病和疾患的方法。该发明还涉及制备此类化合物的工艺以及在此类工艺中有用的中间体。
• [EN] 1-(AMINOPHENYL)-2-PYRROLIDONES AS INTEGRIN INHIBITORS<br/>[FR] 1-(AMINOPHENYL)-2-PYRROLIDONES COMME INHIBITEURS DES INTEGRINES
  申请人：AMGEN INC

  公开号：WO2001044230A1

  公开（公告）日：2001-06-21

  The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as αvβ3, αvβ5, αvβ6, α5β1 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  这项发明包括新的化合物，可用于预防和治疗疾病，例如整合素受体介导的疾病，特别是由整合素受体介导的疾病或病症，例如αvβ3、αvβ5、αvβ6、α5β1等。该发明涵盖了新的化合物、其药学上可接受的盐、制药组合物以及用于预防和治疗此类疾病和疾病的方法。该发明还涉及制备这种化合物的方法以及在这种过程中有用的中间体。
• The Potential Application of Catalytic Antibodies to Protecting Group Removal: Catalytic Antibodies with Broad Substrate Tolerance
  作者：Tingyu Li、Susan Hilton、Kim D. Janda

  DOI：10.1021/ja00113a001

  日期：1995.3

  A catalytic antibody was developed to selectively cleave the alcohol ester of 4-nitrophenylacetyl moiety while also tolerating a wide variety of structural variation on the alcohol portion of the molecule. The basis to the success of this study was that antibody epitope recognition was directed toward only key elements contained within the 4-nitrophenylacetyl group and not the entire haptenic molecule. This study offers the potential application of catalytic antibodies as practical reagents for the selective deprotection of complex multifunctionalized molecules possessing class similar protecting groups. Such a chemoabzymatic approach could eventually minimize synthetic complications which can arise from functional group protection in the synthesis of complex natural products.
• 1-(AMINOPHENYL)-2-PYRROLIDONES AS INTEGRIN INHIBITORS
  申请人：Amgen Inc.,

  公开号：EP1240158A1

  公开（公告）日：2002-09-18